Choreo LLC Sells 4,427 Shares of Novo Nordisk A/S $NVO

Choreo LLC cut its stake in Novo Nordisk A/S (NYSE:NVO) by 3.6% during the second quarter, HoldingsChannel reports. The fund owned 118,601 shares of the company’s stock after selling 4,427 shares during the quarter. Choreo LLC’s holdings in Novo Nordisk A/S were worth $8,186,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the stock. Stone House Investment Management LLC bought a new stake in Novo Nordisk A/S during the first quarter valued at about $30,000. NewSquare Capital LLC increased its position in Novo Nordisk A/S by 174.1% during the 2nd quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock valued at $31,000 after buying an additional 282 shares in the last quarter. Disciplina Capital Management LLC raised its position in shares of Novo Nordisk A/S by 162.3% in the 1st quarter. Disciplina Capital Management LLC now owns 480 shares of the company’s stock valued at $33,000 after purchasing an additional 297 shares during the last quarter. Dagco Inc. purchased a new position in shares of Novo Nordisk A/S in the first quarter worth $35,000. Finally, Mid American Wealth Advisory Group Inc. purchased a new position in Novo Nordisk A/S in the 2nd quarter worth $37,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Performance

NVO opened at $48.75 on Thursday. The firm has a fifty day moving average price of $53.32 and a 200 day moving average price of $59.93. Novo Nordisk A/S has a 1 year low of $43.08 and a 1 year high of $112.52. The stock has a market cap of $217.67 billion, a P/E ratio of 13.39, a P/E/G ratio of 2.33 and a beta of 0.65. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.56.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, November 5th. The company reported $1.02 EPS for the quarter, beating the consensus estimate of $0.77 by $0.25. The company had revenue of $11.79 billion for the quarter, compared to analyst estimates of $11.98 billion. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. Novo Nordisk A/S has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have recently issued reports on NVO shares. HSBC cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday. BNP Paribas Exane raised shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating and set a $54.00 price target for the company in a research report on Wednesday, August 13th. Wall Street Zen cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Saturday, August 2nd. Weiss Ratings upgraded shares of Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday. Finally, BMO Capital Markets reduced their target price on shares of Novo Nordisk A/S from $50.00 to $46.00 and set a “market perform” rating for the company in a report on Tuesday. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $57.40.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.